BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ChromaDex, Inc. Announces Financial Results for the First Quarter 2012


5/11/2012 10:28:39 AM

IRVINE, Calif., May 10, 2012 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC) an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, today announced its financial results for the first quarter of 2012.

ChromaDex announced total revenues, prepared in accordance with United States Generally Accepted Accounting Principles ("GAAP"), of approximately $1.8 million and a net loss attributable to common stockholders of $0.05 per share for the three-month period ended March 31, 2012. As of March 31, 2012, cash, cash equivalents, and marketable securities totaled over $5.8 million.

"In the first quarter we launched our BluScience line of dietary supplements into a major drug chain and a specialty health and nutrition chain," stated Jeffrey Himmel, CEO of ChromaDex. "In addition, we initiated distribution of our BluScience products to a national pharmaceutical distributor and a leading online retailer."

"During the first quarter, we began to supply our patented pTeroPure®ingredient to the equine supplement market. This is another step in achieving our goal to build ChromaDex into a leader in the natural products industry," said Frank Jaksch, Chief Scientific Officer of ChromaDex.

Additional Financial Results & Notes

ChromaDex recorded revenue of $1,785,006 during the first quarter of 2012 as compared to $2,539,245 for the same period in 2011. The net loss attributable to common stockholders for the quarter ended March 31, 2012, was $4,431,853 as compared to a net loss of $1,156,385 for the same period in 2011. The net loss in the first quarter of 2012 was largely impacted by promotions and discounts related to the launch of the Company's BluScience products. In addition, ChromaDex initiated a national advertising campaign through television and radio in support of the launch of its BluScience products, which resulted in additional marketing expenses. The non-cash, share-based compensation expense related to the stock options and other share-based compensation for the first quarter of 2012 was $65,987. The effect of this, which is a "non-GAAP measure," decreased the net loss for the first quarter of 2012 to $4,365,866.

About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure® (www.pteropure.com) pterostilbene for which it has worldwide, exclusive patent pending rights. The company recently launched its BluScience line of dietary supplements, now available at a major drug store chain, a national products retailer, and an online retailer. Capitalizing on the diverse potential applications of the product, ChromaDex is also investigating pTeroPure for the skincare and pharmaceutical markets, among others. pTeroPure is currently being studied in a human clinical trial at the University of Mississippi. For more information about pTeroPure visit www.pteropure.com or call 949-600-9694.

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES